E-resources
PDF-
de Wit, Ronald; de Bono, Johann; Sternberg, Cora N; Fizazi, Karim; Tombal, Bertrand; Wülfing, Christian; Kramer, Gero; Eymard, Jean-Christophe; Bamias, Aristotelis; Carles, Joan; Iacovelli, Roberto; Melichar, Bohuslav; Sverrisdóttir, Ásgerður; Theodore, Christine; Feyerabend, Susan; Helissey, Carole; Ozatilgan, Ayse; Geffriaud-Ricouard, Christine; Castellano, Daniel
The New England journal of medicine, 12/2019, Volume: 381, Issue: 26Journal Article
A randomized trial involving patients with metastatic prostate cancer whose disease progressed after receipt of docetaxel and hormonal therapy showed that cabazitaxel was superior to an androgen-signaling–targeted agent in extending imaging-based progression-free survival, overall survival, and PSA response.
